Professional Documents
Culture Documents
Abstract There is no doubt that antimicrobial agents have saved the human race from a lot of suffering due to infectious disease burden. Without antimicrobial agents, millions of people would have succumbed to infectious diseases. Man has survived the accidental wrath of microorganisms using antimicrobial agents and other mechanisms that keep them at bay. Hardly years after the discovery and use of the first antibiotics was observation made of organisms that still survived the effects of the antimicrobial agents. That was the beginning of the suspicion that different microorganisms were getting a way around previously harmful agents that is known today as antimicrobial resistance. Microbial resistance to antimicrobial agents was not a new phenomenon for it had been constantly used as competitive/survival mechanisms by microorganisms against others. These mechanisms have been well documented. This chapter therefore gives a brief overview of the mechanisms of resistance by bacteria against antimicrobial agents, and the mechanisms, levels, and patterns of resistance to the different microorganisms in developing countries are dealt with in detail elsewhere in the book. Understanding the mechanisms of resistance is important in order to define better ways to keep existing agents useful for a little longer but also to help in the design of better antimicrobial agents that are not affected by the currently known, predicted, or unknown mechanisms of resistance.
2.1 Introduction
Microorganisms have existed on the earth for more than 3.8 billion years and exhibit the greatest genetic and metabolic diversity. They are an essential component of the biosphere and serve an important role in the maintenance and sustainability of ecosystems. It is believed that they compose about 50% of
D.K. Byarugaba (*) Department of Veterinary Microbiology and Parasitology, Faculty of Veterinary Medicine, Makerere University, Kampala, Uganda e-mail: dkb@vetmed.mak.ac.ug
A. de J. Sosa et al. (eds.), Antimicrobial Resistance in Developing Countries, DOI 10.1007/978-0-387-89370-9_2, Springer ScienceBusiness Media, LLC 2009
15
16
D.K. Byarugaba
the living biomass. In order to survive, they have evolved mechanisms that enable them to respond to selective pressure exerted by various environments and competitive challenges. The disease-causing microorganisms have particularly been vulnerable to mans selfishness for survival who has sought to deprive them of their habitat using antimicrobial agents. These microorganisms have responded by developing resistance mechanisms to fight off this offensive. Currently antimicrobial resistance among bacteria, viruses, parasites, and other disease-causing organisms is a serious threat to infectious disease management globally. Antibiotics were discovered in the middle of the nineteenth century and brought down the threat of infectious diseases which had devastated the human race. However, soon after the discovery of penicillin in 1940, a number of treatment failures and occurrence of some bacteria such as staphylococci which were no longer sensitive to penicillin started being noticed. This marked the beginning of the error of antimicrobial resistance. Scientific antibiotic discovery started in the early 1900s by Alexander Fleming, who observed inhibition of growth on his agar plate on which he was growing Staphylococcus spp. It was later found that a microorganism that was later to be called Penicillium notatum was the cause of the inhibition of the Staphylococcus around it as a result of excreting some chemical into the media. That marked the beginning of the discovery of penicillin which together with several other different antimicrobial agents was later to save millions of humans and animals from infectious disease-causing organisms. The detailed history and documentation of mans search for agents to cure infectious disease has been described extensively elsewhere. The observation of Staphylococci spp. that could still grow in the presence of penicillin was the beginning of the era of antimicrobial resistance and the realization that after all the drugs that were described as magical bullets were not to last for long due to the selective pressure that was being exerted by the use of these agents. However, the complacency between the 1940s and the 1970s that infectious microorganisms had been dealt a blow was later proved to be a misplaced belief that available antibiotics would always effectively treat all infections. Nevertheless, antimicrobial agents have improved the management of infectious diseases up to date. Increasing prevalence of resistance has been reported in many pathogens over the years in different regions of the world including developing countries (Byarugaba, 2005). This has been attributed to changing microbial characteristics, selective pressures of antimicrobial use, and societal and technological changes that enhance the development and transmission of drug-resistant organisms. Although antimicrobial resistance is a natural biological phenomenon, it often enhanced as a consequence of infectious agents adaptation to exposure to antimicrobials used in humans or agriculture and the widespread use of disinfectants at the farm and the household levels (Walsh, 2000). It is now accepted that antimicrobial use is the single most important factor
17
responsible for increased antimicrobial resistance (Aarestrup et al., 2001; Byarugaba, 2004). In general, the reasons for increasing resistance levels include the following:
suboptimal use of antimicrobials for prophylaxis and treatment of infection, noncompliance with infection-control practices, prolonged hospitalization, increased number and duration of intensivecare-unit stays,
multiple comorbidities in hospitalized patients, increased use of invasive devices and catheters, ineffective infection-control practices, transfer of colonized patients from
hospital to hospital,
grouping of colonized patients in long-term-care facilities, antibiotic use in agriculture and household chores, and increasing national and international travel.
The level of antibiotic resistance is dependent on the following:
the population of organisms that spontaneously acquire resistance mechanisms as a result of selective pressure either from antibiotic use or otherwise,
18
D.K. Byarugaba
of antimicrobial agents can be categorized further based on the structure of the bacteria or the function that is affected by the agents. These include generally the following:
Inhibition of the cell wall synthesis Inhibition of ribosome function Inhibition of nucleic acid synthesis Inhibition of folate metabolism Inhibition of cell membrane function
The chemical structure and details of these mechanisms have been described in several literature elsewhere and a summary of the mode of action for the major classes is provided in Table 2.1.
Table 2.1 Summary of mechanisms of action of antimicrobial agents Group of antimicrobial agents Effect on bacteria Mode of action in general Penicillins Cephalosporins Carbanepems Polypeptide antibiotics Quinolones Metronidazole Rifamycins Lincosamides Aminoglycosides Macrolides Tetracyclines Chloramphenicol Sulfonamides Bactericidal Bactericidal Bactericidal Bactericidal Bactericidal Bactericidal Bactericidal Bactericidal Bactericidal Bacteriostatic Bacteriostatic Bacteriostatic Bacteriostatic Inhibition of cell wall synthesis Inhibition of cell wall synthesis Inhibition of cell wall synthesis Inhibition of cell wall synthesis Inhibits DNA synthesis Inhibits DNA synthesis Inhibitions of RNA transcription Inhibition of protein synthesis Inhibition of protein synthesis Inhibition of protein synthesis Inhibition of protein synthesis Inhibition of protein synthesis Competitive inhibition
19
Resistance can be described in two ways: a) intrinsic or natural whereby microorganisms naturally do not posses target sites for the drugs and therefore the drug does not affect them or they naturally have low permeability to those agents because of the differences in the chemical nature of the drug and the microbial membrane structures especially for those that require entry into the microbial cell in order to effect their action or b) acquired resistance whereby a naturally susceptible microorganism acquires ways of not being affected by the drug. Acquired resistance mechanisms can occur through various ways as described by Fluit et al. (2001) summarized in Box 2.1 and illustrated in Fig. 2.1. Box 2.1 Mechanisms for acquired resistance the presence of an enzyme that inactivates the antimicrobial agent the presence of an alternative enzyme for the enzyme that is inhibited by the antimicrobial agent a mutation in the antimicrobial agents target, which reduces the binding of the antimicrobial agent post-transcriptional or post-translational modification of the antimicrobial agents target, which reduces binding of the antimicrobial agent reduced uptake of the antimicrobial agent active efflux of the antimicrobial agent overproduction of the target of the antimicrobial agent expression or suppression of a gene in vivo in contrast to the situation in vitro previously unrecognized mechanisms
20 Fig. 2.1 Illustration of how some antimicrobial agents are rendered ineffective (Adopted from http:// www.chembio.uoguelph.ca)
D.K. Byarugaba
susceptibility to inhibitors, genetic localization (plasmidic or chromosomal), and gene or amino acid protein sequence. The functional classification scheme of b-lactamases proposed by Bush, Jacoby and Medeiros (1995) defines four groups according to their substrate and inhibitor profiles:
Group 1 are cephalosporinases that are not well inhibited by clavulanic acid; Group 2 are penicillinases, cephalosporinases, and broad-spectrum b-lactamases that are generally inhibited by active site-directed b-lactamase inhibitors;
21
chlamydiae, mycoplasmas, and rickettsiae, and protozoan parasites. Examples of these include drugs such as tetracycline, doxycycline, minocycline, and oxtetracycline. Resistance to these agents occurs mainly through three mechanisms (Roberts, 1996), namely
22
D.K. Byarugaba
alterations in drug target enzymes and alterations that limit the permeability of the drug to the target.
23
The target enzymes are most commonly altered in domains near the enzymeactive sites, and in some cases reduced drug-binding affinity. In gram-negative organisms, DNA gyrase seems to be the primary target for all quinolones. In gram-positive organisms, topoisomerase IV or DNA gyrase is the primary target depending on the fluoroquinolones considered. In almost all instances, amino acid substitutions within the quinolone resistance-determining region (QRDR) involve the replacement of a hydroxyl group with a bulky hydrophobic residue. Mutations in gyrA induce changes in the binding-site conformation and/or charge that may be important for quinoloneDNA gyrase interaction (Everett and Piddock, 1998). Changes in the cell envelope of gram-negative bacteria, particularly in the outer membrane, have been associated with decreased uptake and increased resistance to fluoroquinolones, and this has not been demonstrated in gram-positive bacteria.
Post-transcriptional modifications of the 23S rRNA by the adenine-N6methyltransferase which alters a site in 23S rRNA common to the binding of MLSB antibiotics which also confers cross-resistance to MLSB antibiotics (MLSB-resistant phenotype) and remains the most frequent mechanism of resistance. In general, genes encoding these methylases have been designated erm (erythromycin ribosome methylation). Efflux proteins, which pump these antibiotics out of the cell or the cellular membrane, keeping intracellular concentrations low and ribosomes free from antibiotic, and these have become more frequent in gram-positive populations and often coded for by mef, msr, and vga genes. Hydrolytic enzymes which hydrolyze streptogramin B or modify the antibiotic by adding an acetyl group (acetyltransferases) to streptogramin A have also been described and these confer resistance to structurally related drugs.
24
D.K. Byarugaba
preventing cross-linking of the peptidoglycan chain and thus are largely effective against gram-positive microorganisms which poses a bigger layer of the peptidoglycan although not all gram-positive organisms are susceptible to these agents. High-level resistance to vancomycin is encoded by the vanA gene that results in the production of VanA, a novel D-Ala-D-Ala ligase resulting in the rebuilding of the peptidoglycan side chain to express D-alanyl-D-lactate type which has less affinity for glycopeptides (Leclerq and Courvalin, 1997). There are also other proteins in this gene cluster that are necessary for resistance including VanH and VanX, as well as VanB which confers moderate levels of resistance to vancomycin and susceptibility to teicoplanin. Vancomycin gained clinical importance because it was traditionally reserved as a last resort treatment for resistant infections especially of methicillin-resistant Staphylococcus aureus (MRSA). The emergency of vancomycin-resistant organisms has deprived the usefulness of this drug.
overproduction of the host DHFR, mutations in the structural gene for DHFR, and acquisition of a gene (dfr) encoding a resistant DHFR enzyme which is the
most resistant mechanism in clinical isolates. At least 15 DHFR enzyme types are known based on their properties and sequence homology (Schmitz and Fluit, 1999).
25
ability to capture genes, notably those encoding antibiotic resistance, by sitespecific recombination, and they have an intergrase gene (int), a nearby recombination site (attI), and a promoter, Pant (Hall, 1997). Integrons seem to have a major role in the spread of multidrug resistance in gram-negative bacteria but integrons in gram-positive bacteria have also been described (Dessen et al., 2001). Class 1 integrons are often associated with the sulfonamide resistance gene sulI and are the most common integrons. Class 2 integrons are associated with Tn7. The majority of genes encode antibiotic disinfectant resistance, including resistance to aminoglycosides, penicillins, cephalosporins, trimethoprim, tetracycline, erythromycin, and chloramphenicol.
References
Aarestrup, F. M., Seyfarth, A. M., Emborg, H. D., Pedersen, K., Hendriksen, R. S., and Bager, F. 2001. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob. Agents Chemother. 45: 20542059. Bush, K., Jacoby, G. A., and Medeiros A. A. 1995. A functional classification scheme for beta lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother 39(6): 12111233. Butaye, P., Cloeckaert, A., and Schwarz, S. 2003. Mobile genes coding for efflux-mediated antimicrobial resistance in Gram-positive and Gram-negative bacteria. Int. J. Antimicrob. Agents 22: 205210. Byarugaba, D. K. 2004. A view on antmicrobial resistance in developing countries and responsible risk factors. Int. J. Antimicrob. Agents 24: 105110. Byarugaba, D. K. (2005). Antimicrobial resistance and its containment in developing countries. In Antibiotic Policies: Theory and Practice, ed. I. Gould and V. Meer, pp 617646. New York: Springer. Dessen, A., Di Guilmi, A. M., Vernet, T., and Dideberg, O. 2001. Molecular mechanisms of antibiotic resistance in gram-positive pathogens. Curr. Drug Targets Infect. Dis.. 1:6377 Enne, V. I., Livermore, D. M., Stephens, P., and Hall, L. M. C. 2001. Persistence of sulfonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:13251328 Everett, M. J. and L. J. V. Piddock. 1998. Mechanisms of resistance to fluoroquinolones. In Quinolone Antibacterials ed. J. Kuhlmann, A. Dahlhoff, and H. J. Zeiler pp. 259297. Berlin:Springer-Verlag KG. Fluit, A. C., Visser, M. R., and Schmitz, F. J. 2001. Molecular detection of antimicrobial resistance. Clin. Microbiol. Rev. 14:83671. Hall, R. M. 1997. Mobile gene cassettes and integrons: moving antibiotic resistance genes in Gram-negative bacteria. Ciba Found. Symp. 207: 192205 Hooper, D. C. 1999. Mechanisms of fluoroquinolone resistance. Drug Resist. Updates 2:3855 Johnston, N. J., de Azavedo, J. C., Kellner, J. D., and Low, D. E. 1998. Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:24252426 Kehrenberg, C., Schulze-Tanzil, G., Martel, J. L., Chaslus-Dancla, E., and Schwarz, S. 2001. Antimicrobial resistance in Pasteurella and Mannheimia: epidemiology and genetic basis. Vet. Res. 32(34): 323339.
26
D.K. Byarugaba
Leclerq, R. and Courvalin, P.. 1997. Resistance to glycopeptides in enterococci. Clin. Infect. Dis. 24: 545556 Levy, S. B. 1988. Tetracycline resistance determinants are widespread. ASM News. 54:418421. Quintiliani, R. and Courvalin, P. 1995. Mechanisms of resistance to antimicrobial agents, In Manual of Clinical Microbiology, ed P. R. Murray, E. J. Baron, M. A. Pfaller, F. R. Tenover, and R. H. Yolken, pp. 13081326. Washington, D.C: ASM Press. Roberts, M. C. 1996. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol. Rev. 19:124 Schmitz, F. J. and Fluit. A. C. 1999. Mechanisms of resistance. In Infectious Diseases. ed D. Armstrong, and S. Cohen, pp. 7.2.17.2.14 London: Mosby, Ltd., Shaw, K. J., Rather, P. N., Have, R. S., and Miller, G. M. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside modifying enzymes. Microbiol. Rev. 57: 138163 Taylor, D. E. and Chau, A. 1996. Tetracycline resistance mediated by ribosomal protection. Antimicrob. Agents Chemother. 40: 15 Thomson, C. J. 1993. Trimethoprim and brodimoprim resistance of gram-positive and gramnegative bacteria. J. Chemother. 5: 458464 de ` s, G., Bentorcha, F., Delbos, F., Gaspar, E., and Horaud, T. 1993. Traced, P., de Cespe Study of heterogeneity of chloramphenicol acetyltransferase (CAT) genes in streptococci and enterococci by polymerase chain reaction: characterization of a new CAT determinant. Antimicrob. Agents Chemother. 37: 25932598 Walsh, C. 2000. Molecular mechanisms that confer antibacterial drug resistance. Nature 406: 775781
http://www.springer.com/978-0-387-89369-3